Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients

Cabré, Anna; Lázaro, Iolanda; Girona, Josefa; Manzanares, José María; Marimón, Francesc; Plana, Núria; Heras, Mercedes; Masana, Luís

doi:10.1016/j.atherosclerosis.2007.04.045

Cited by 136 publications

(118 citation statements)

References 30 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…In agreement with these findings, serum AFABP values were positively and independently correlated with markers of the metabolic syndrome, including waist circumference, blood pressure, dyslipidaemia, fasting insulin and HOMA of insulin resistance, in the initial study [59]. A similar association of circulating AFABP with facets of the metabolic syndrome has also been shown in other studies [12,66,67,[70][71][72][73].…”

Section: Controlssupporting

confidence: 76%

“…Thus, in the first description of circulating AFABP, Xu et al observed a significant upregulation of AFABP levels in obesity [59]. An increase in AFABP serum levels in patients with the metabolic syndrome compared with controls has also been described in various independent studies [12,66,67]. Furthermore, circulating AFABP has been reported to be elevated in patients with familial combined hyperlipidaemia [68] and in those with non-alcoholic fatty liver disease, a disorder regarded as the hepatic manifestation of the metabolic syndrome [69].…”

Section: Controlsmentioning

confidence: 89%

“…Furthermore, cyclic adenosine monophosphate induces AFABP gene expression during adipocyte differentiation by relieving the inhibitory effect of a negative regulatory element in the AFABP promoter [10]. Moreover, insulin-sensitising and pro-adipogenic peroxisome proliferator-activated receptor (PPAR)γ agonists induce AFABP production and secretion [12,13]. In addition, AFABP mRNA and protein production are elevated in subcutaneous adipose tissue compared with the visceral depot in lean and obese humans [14].…”

Section: Production and Structure Of Afabpmentioning

confidence: 99%

See 2 more Smart Citations

Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?

2012

View full text Add to dashboard Cite

Adipocyte fatty acid binding protein (AFABP, also known as aP2 and FABP4) has recently been introduced as a novel fat-derived circulating protein. AFABP serum concentrations are positively correlated with markers of the metabolic syndrome and vascular disease in various cross-sectional and interventional studies. Furthermore, a small set of prospective studies indicates that high AFABP serum levels at baseline predict the risk for metabolic and vascular morbidity and mortality. Studies in Afabp (also known as Fabp4) knockout mice and AFABP inhibitortreated animals suggest that total AFABP promotes insulin resistance, hypertriacylglycerolaemia and atherosclerosis by ligand/ligand delivery, as well as ligand-independent mechanisms. In contrast, the pathophysiological significance of circulating AFABP and the mechanisms leading to its release remain to be established. The current review summarises recent findings on the regulation and potential role of AFABP in metabolic and vascular disease.

show abstract

Section: Controlssupporting

confidence: 76%

Section: Controlsmentioning

confidence: 89%

Section: Production and Structure Of Afabpmentioning

confidence: 99%

See 1 more Smart Citation

Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?

2012

View full text Add to dashboard Cite

show abstract

“…The function of circulating aP2 is unclear, but it may link obesity, inflammation and the metabolic syndrome. 3 In adult studies, circulating aP2 concentrations correlate with insulin resistance and dyslipidemia [4][5][6] and predict development of the metabolic syndrome. 7 aP2 has been linked to inflammation in atherosclerotic lesions 2,8,9 and in allergic airway disease.…”

Section: Introductionmentioning

confidence: 99%

The increase of fatty acid-binding protein aP2 in overweight and obese children: interactions with dietary fat and impact on measures of subclinical inflammation

Aeberli¹,

Beljean²,

Lehmann³

et al. 2008

Int J Obes

View full text Add to dashboard Cite

Background:In adults, circulating aP2 may link obesity, inflammation and the metabolic syndrome, but there are few data in children. Experimental models support that dietary factors, particularly dietary fat, may be major determinants of phenotype. Objective: The aim of this study was to investigate, in normal, overweight and obese children, the relationships among aP2, the metabolic syndrome, inflammation and diet. Design: This was a cross-sectional study conducted in Northern Switzerland. Subjects: Subjects for this study were 6-to 14-year-old, prepubertal and early pubertal, normal weight, overweight and obese children (n ¼ 124). Main outcome measures: Body mass index (BMI), body fat percent, waist-to-hip ratio, blood pressure, circulating aP2, fasting insulin, C-reactive protein (CRP), plasma lipids and dietary intakes of macro-and micronutrients were determined. Results: Circulating aP2 markedly increased with increasing central and total adiposity, and predicted measures of insulin resistance. Independent of BMI standard deviation scores and puberty, aP2 correlated with intake of the antioxidant vitamins A, C and E as well as circulating concentrations of CRP, leptin and low-density lipoprotein cholesterol. Children with lower aP2 concentrations consuming high-fat diets did not show an increase in fasting insulin or CRP, whereas those with higher aP2 concentrations showed marked increases in these measures with high intakes of fat or saturated fat. Conclusions: Increased central and overall adiposity in children are associated with higher circulating aP2 concentrations. In children with high dietary intakes of total fat and saturated fat, but not those with low intakes, higher aP2 concentrations are associated with measures of insulin resistance and inflammation.

show abstract

“…Furthermore, elevation of the circulating FABP4 level is associated with obesity, insulin resistance, hypertension, cardiac dysfunction, dyslipidemia, and atherosclerosis 15, 16, 17, 18, 19, 20, 21. Several drugs for dyslipidemia, diabetes mellitus, and hypertension have been reported to modulate FABP4 levels 22, 23, 24, 25, 26, 27, 28…”

Section: Introductionmentioning

confidence: 99%

Ectopic Fatty Acid–Binding Protein 4 Expression in the Vascular Endothelium is Involved in Neointima Formation After Vascular Injury

Fuseya

Furuhashi

Matsumoto

et al. 2017

JAHA

View full text Add to dashboard Cite

BackgroundFatty acid‐binding protein 4 (FABP4) is expressed in adipocytes, macrophages, and endothelial cells of capillaries but not arteries. FABP4 is secreted from adipocytes in association with lipolysis, and an elevated circulating FABP4 level is associated with obesity, insulin resistance, and atherosclerosis. However, little is known about the link between FABP4 and endovascular injury. We investigated the involvement of ectopic FABP4 expression in endothelial cells in neointima hyperplasia after vascular injury.Methods and ResultsFemoral arteries of 8‐week‐old male mice were subjected to wire‐induced vascular injury. After 4 weeks, immunofluorescence staining showed that FABP4 was ectopically expressed in endothelial cells of the hyperplastic neointima. Neointima formation determined by intima area and intima to media ratio was significantly decreased in FABP4‐defficient mice compared with that in wild‐type mice. Adenovirus‐mediated overexpression of FABP4 in human coronary artery endothelial cells (HCAECs) in vitro increased inflammatory cytokines and decreased phosphorylation of nitric oxide synthase 3. Furthermore, FABP4 was secreted from HCAECs. Treatment of human coronary smooth muscle cells or HCAECs with the conditioned medium of Fabp4‐overexpressed HCAECs or recombinant FABP4 significantly increased gene expression of inflammatory cytokines and proliferation‐ and adhesion‐related molecules in cells, promoted cell proliferation and migration of human coronary smooth muscle cells, and decreased phosphorylation of nitric oxide synthase 3 in HCAECs, which were attenuated in the presence of an anti‐FABP4 antibody.ConclusionsEctopic expression and secretion of FABP4 in vascular endothelial cells contribute to neointima formation after vascular injury. Suppression of ectopic FABP4 in the vascular endothelium would be a novel strategy against post‐angioplasty vascular restenosis.

show abstract

Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients

Cited by 136 publications

References 30 publications

Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?

Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?

The increase of fatty acid-binding protein aP2 in overweight and obese children: interactions with dietary fat and impact on measures of subclinical inflammation

Ectopic Fatty Acid–Binding Protein 4 Expression in the Vascular Endothelium is Involved in Neointima Formation After Vascular Injury

Contact Info

Product

Resources

About